Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nuwellis (NUWE) EPS (Weighted Average and Diluted) (2011 - 2026)

Nuwellis posted quarterly EPS (Weighted Average and Diluted) of -$2.19 for Q1 2026, up 92.43% year-on-year from -$1.14 in Q1 2025, and down 115.51% on a QoQ basis from $14.12 in Q4 2025.

Nuwellis (NUWE) has 9 years of EPS (Weighted Average and Diluted) data on file, last reported at -$2.19 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 92.43% year-over-year to -$2.19; the trailing twelve-month figure through Mar 2026 stood at -$48.5 (up 94.94% YoY), and the FY2025 full-year result was -$25.39, up 92.81% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.19, down from $14.12 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $73.23 in Q3 2024 and bottomed at -$791.82 in Q2 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$28.93 (2025), against an average of -$77.3.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 215.74% in 2024, while the deepest fall reached 7899.62% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $36.3 in 2022, then tumbled by 107.27% to -$2.64 in 2023, then slumped by 7899.62% to -$211.19 in 2024, then surged by 106.69% to $14.12 in 2025, then sank by 115.51% to -$2.19 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$2.19 (Q1 2026), $14.12 (Q4 2025), and $0.56 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.61
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.93
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.89
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.90
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.66
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.51
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.85
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 2.24
10 Nuwellis 1.45 Mn -630,292.49 1.68 Mn -2.19

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -2.19
Dec 31, 2025 14.12
Sep 30, 2025 0.56
Jun 30, 2025 -60.99
Mar 31, 2025 -0.69
Dec 31, 2024 -211.19
Sep 30, 2024 73.23
Jun 30, 2024 -791.82
Mar 31, 2024 -24.11
Dec 31, 2023 -2.64
Sep 30, 2023 -63.27
Jun 30, 2023 -127.65
Mar 31, 2023 -5.76
Dec 31, 2022 36.30
Sep 30, 2022 -36.72
Jun 30, 2022 -40.67
Mar 31, 2022 -42.45
Dec 31, 2021 -282.64
Sep 30, 2021 -0.75
Jun 30, 2021 -0.72
Mar 31, 2021 -1.62
Dec 31, 2020 0.60
Sep 30, 2020 -2.08
Jun 30, 2020 -3.10
Mar 31, 2020 -11.54
Sep 30, 2012 -0.49
Jun 30, 2012 -0.42
Mar 31, 2012 -0.66
Sep 30, 2011 -0.89
Jun 30, 2011 -0.68
Mar 31, 2011 -0.55